Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K/AKT inhibition
Our preclinical data highlighted the potential synergistic efficacy of chidamide and selinexor in targeting HGBL-DHL, providing a rationale for further clinical investigation of this therapeutic combination for the treatment of this refractory disease.
Authors
- Xinguo ZHUANG
- Dongmei Qin
- Beibei Xu (ORCID: https://orcid.org/0000-0003-3507-9321)
- Jie Zhou (ORCID: https://orcid.org/0000-0002-1754-3744)
- Hui Zhou
- Bozhang Chen
- Jiazhen Lin
- Jie Zha
- Shuman Jia
- Mingxin Zhuang
Institutions
- Xiamen University (CN)
- First Affiliated Hospital of Xiamen University (CN)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1186/s13148-026-02056-6
- Primary Topic
- Nuclear Structure and Function
- Type
- article
- Field-Weighted Citation Impact
- 0.00